

**Cardiomyopathy in adults**

<b>Bibliographic reference</b>	<b>Chicco et al. (2010)</b>
<b>Study type</b>	Cross-sectional survey
<b>Study quality</b>	<p>The Joanna Briggs Institute Prevalence Critical Appraisal Tool (<a href="http://ijhpm.com/article_2870_607.html">http://ijhpm.com/article_2870_607.html</a>)</p> <ol style="list-style-type: none"> <li>1. Was the sample representative of the target population? YES</li> <li>2. Were study participants recruited in an appropriate way? NO – Unclear is consecutive sample recruited</li> <li>3. Was the sample size adequate? YES</li> <li>4. Were the study subjects and the setting described in detail? YES</li> <li>5. Was the data analysis conducted with sufficient coverage of the identified sample? YES</li> <li>6. Were objective, standard criteria used for the measurement of the condition? YES</li> <li>7. Was the condition measured reliably? YES</li> <li>8. Was there appropriate statistical analysis? YES</li> <li>9. Are all important confounding factors/subgroups/differences identified and accounted for? YES</li> <li>10. Were subpopulations identified using objective criteria? NA</li> </ol> <p>Overall risk of bias = MODERATE</p>
<b>Country</b>	Italy
<b>Number of patients</b>	<p>N=104 adults with idiopathic dilated cardiomyopathy</p> <p>N=63 diseased controls</p> <p>N=101 healthy controls</p>
<b>Study population</b>	<p>Inclusion: adults patients with idiopathic dilated cardiomyopathy who underwent screening between April 2007 and February 2008</p> <p>Characteristics of those with idiopathic dilated cardiomyopathy:</p> <p>59 males/45 females, median 52 years (range 28-61)</p>
<b>Control</b>	<p>Diseased controls: 43 males/20 females, median 59 years (range 39-72)</p> <p>Healthy controls: apparently healthy nurses and residents working in cardiology or paediatric departments: 60 males/41 females,</p>

Appendix D: Evidence Tables

	median 40 years (range 27-50)
<b>Details of coeliac testing</b>	IgA anti-tTG (Eu-tTG Quick, Eurospital, Italy) IgA and IgG serum (ELISA, Eu-tTG IgG, human IgA, Eurospital, Italy) EMA IgA (immunofluorescence assay on human umbilical cord cryosections) Biopsy for all with positive anti-tTG or EMA
<b>Results</b>	2.9% (3/104) with idiopathic dilated cardiomyopathy had biopsy-confirmed CD (Marsh type IIIc; 2 males, 1 female) 0% (0/63) diseased controls 1% (1/101) of controls had biopsy-confirmed CD (Marsh type IIIc)
<b>Source of funding</b>	Institute of Child Health IRCCS “Burlo Garofolo” Trieste
<b>Conflicts of interest</b>	Not reported
<b>Comments</b>	

Definitions of abbreviations are given at the end of this document.

<b>Bibliographic reference</b>	<b>de Menzes et al. (2012)</b>
<b>Study type</b>	Cross-sectional survey
<b>Study quality</b>	The Joanna Briggs Institute Prevalence Critical Appraisal Tool ( <a href="http://ijhpm.com/article_2870_607.html">http://ijhpm.com/article_2870_607.html</a> ) <ol style="list-style-type: none"> <li>1. Was the sample representative of the target population? YES</li> <li>2. Were study participants recruited in an appropriate way? NO – Unclear if consecutive sample recruited</li> <li>3. Was the sample size adequate? YES</li> <li>4. Were the study subjects and the setting described in detail? YES</li> <li>5. Was the data analysis conducted with sufficient coverage of the identified sample? YES</li> <li>6. Were objective, standard criteria used for the measurement of the condition? YES</li> <li>7. Was the condition measured reliably? YES</li> <li>8. Was there appropriate statistical analysis? YES</li> <li>9. Are all important confounding factors/subgroups/differences identified and accounted for? YES</li> <li>10. Were subpopulations identified using objective criteria? NA</li> </ol> Overall risk of bias = MODERATE
<b>Country</b>	Brazil
<b>Number of patients</b>	N=56 children and adolescents with dilated cardiomyopathy or myocarditis
<b>Study population</b>	Inclusion: children and adolescents with a clinical diagnosis of dilated cardiomyopathy or myocarditis who were seen at a paediatric

Appendix D: Evidence Tables

	cardiology service between December 2009 and November 2010; children were older than 1 (to ensure gluten exposure) Exclusion: previous CD diagnosis Median age 96 months (from 12 to 225 months / 1 and 18 years) 57% (32) female
<b>Control</b>	None
<b>Details of coeliac testing</b>	EMA IgA (Immco Diagnostics, Genbiotech; > 20 U/ml were positive) tTG IgA (Orgentec, Diagnostika; > 10 U/ml were positive) Serum IgA was also determined to rule out IgA deficiency intestinal biopsy if positive serology
<b>Results</b>	Only one had tTGA serum positive levels and also had intraepithelial lymphocytosis and total villous atrophy.  1.8% (95% CI 0.04-9.5%) were biopsy-confirmed CD
<b>Source of funding</b>	Not reported
<b>Conflicts of interest</b>	Study reports none related to this article
<b>Comments</b>	

Definitions of abbreviations are given at the end of this document.

<b>Bibliographic reference</b>	<b>Frustaci et al. (2002)</b>
<b>Study type</b>	Case-control
<b>Study quality</b>	The Joanna Briggs Institute Prevalence Critical Appraisal Tool ( <a href="http://ijhpm.com/article_2870_607.html">http://ijhpm.com/article_2870_607.html</a> ) <ol style="list-style-type: none"> <li>1. Was the sample representative of the target population? YES</li> <li>2. Were study participants recruited in an appropriate way? Yes (consecutive sample recruited)</li> <li>3. Was the sample size adequate? YES</li> <li>4. Were the study subjects and the setting described in detail? YES</li> <li>5. Was the data analysis conducted with sufficient coverage of the identified sample? YES</li> <li>6. Were objective, standard criteria used for the measurement of the condition? YES</li> <li>7. Was the condition measured reliably? YES</li> <li>8. Was there appropriate statistical analysis? YES</li> <li>9. Are all important confounding factors/subgroups/differences identified and accounted for? YES</li> <li>10. Were subpopulations identified using objective criteria? NA</li> </ol>

Appendix D: Evidence Tables

	Overall risk of bias = LOW
<b>Country</b>	Italy
<b>Number of patients</b>	N=187 adults
<b>Study population</b>	Inclusion: consecutive patients with myocarditis admitted with either heart failure (N=110), with cardiac arrhythmias (N=77), N=118 male, mean age 41.7±14.3yrs, none had IgA deficiency
<b>Control</b>	none
<b>Details of coeliac testing</b>	
<b>Results</b>	N=13 +ve IgA-tTG N=9 +ve for AEA and had iron-deficiency anaemia and had histologic evidence of coeliac disease  Prevalence of coeliac disease 4.4% with myocarditis vs. N=1 (0.3%), p<0.003
<b>Source of funding</b>	MURST project
<b>Conflicts of interest</b>	
<b>Comments</b>	

Definitions of abbreviations are given at the end of this document.

<b>Bibliographic reference</b>	<b>Vizzardi et al. (2008)</b>
<b>Study type</b>	Cross-sectional data from case series
<b>Study quality</b>	The Joanna Briggs Institute Prevalence Critical Appraisal Tool ( <a href="http://ijhpm.com/article_2870_607.html">http://ijhpm.com/article_2870_607.html</a> ) <ol style="list-style-type: none"> <li>1. Was the sample representative of the target population? YES</li> <li>2. Were study participants recruited in an appropriate way? Yes (Consecutive sample recruited)</li> <li>3. Was the sample size adequate? YES</li> <li>4. Were the study subjects and the setting described in detail? YES</li> <li>5. Was the data analysis conducted with sufficient coverage of the identified sample? YES</li> <li>6. Were objective, standard criteria used for the measurement of the condition? YES</li> <li>7. Was the condition measured reliably? YES</li> <li>8. Was there appropriate statistical analysis? YES</li> <li>9. Are all important confounding factors/subgroups/differences identified and accounted for? YES</li> </ol>

Appendix D: Evidence Tables

	10. Were subpopulations identified using objective criteria? NA Overall risk of bias = LOW
<b>Country</b>	Italy
<b>Number of patients</b>	N=350 with idiopathic or ischaemic dilated cardiomyopathy
<b>Study population</b>	Patients: consecutive patients referred to the Heart Failure Centres of the Cardiology Department of a hospital from April to December 2005 who were unaware of a CD diagnosis at enrolment N=182 idiopathic dilated cardiomyopathy; mean 52 ± 12 years; 128 male, 54 female N=168 ischaemic dilated cardiomyopathy; mean 64 ± 14 years; 130 male, 38 female (patients were significantly different in terms of age [p<0.0001] and ejection fraction [p<0.005])
<b>Control</b>	none
<b>Details of coeliac testing</b>	tTG antibody (CELIKEY™ with human recombinant antigen, Pharmacia&Upjohn, Sweden; > 7 U/ml cut-off value) and EMA (immunofluorescence on monkey oesophagus slides, Antiendomysium®, Eurospital, Italy) for those tTG positive Biopsy for those serologically positive (using Marsh classification)
<b>Results</b>	<b>0.6% (2) tested positive for tTG and EMA antibodies; both patients had complete villous atrophy on biopsy</b> Both had been on optimized therapy for heart failure for > 2 years
<b>Source of funding</b>	Not reported
<b>Conflicts of interest</b>	Not reported
<b>Comments</b>	

Definitions of abbreviations are given at the end of this document.